Clinical

Data from the secondary analysis show that the improvements seen in health-related quality of life (HRQOL) translated into clinical improvements.

The case is believed to be just the second reported in the scientific literature.

Pediatric and adult patients with a diagnosis of spinal muscular atrophy (SMA) benefitted from nusinersen treatment in that they were able to prolong their walking time.

Patients who had non–small cell lung cancer (NSCLC) with homologous recombination gene mutations had better outcomes, although no single gene in the pathway appeared to have a causal role.

Considerations for insurance preauthorization and reauthorization are explored by a key opinion leader.

Patients and families facing a Rett syndrome diagnosis experience an array of burdens.

Drs Chitre and Weaver share their finals thoughts, highlighting key contributors to long-term outcomes for patients with major depressive disorder.

Early effective treatment strategies can have a significant impact on long-term effects for patients with MDD.

The findings include the identification of a 12-gene signature that could be used to categorize patients as high or low risk.

The researchers hypothesize that SARS-CoV-2 infection may have triggered thymic inflammation, spearheading initial expression of muscle-like epitopes and T-cell dysregulation.

The new report found no evidence that second-generation tyrosine kinase inhibitors (TKIs) were more likely to lead to Clostridioides difficile infection (CDI) in patients with lung cancer.

During 2022, the FDA approved 2 chimeric antigen receptor (CAR) T-cell therapies for use in second-line treatment, offering new treatment choices but raising the question: What options remain once a patient relapses after CAR T?

Levels of certain biomarkers of inflammation in prurigo nodularis were evaluated between patients with and without the chronic inflammatory skin disorder, with the goal of showing potential for precision medicine in prurigo nodularis.

Research presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition examined how certain patient and demographic characteristics that may be related to socioeconomic disparities impact the risk of hematological cancers; the influence of diabetes on chronic myeloid leukemia; and 2 updates on ponatinib.

A review showed lifestyle intervention was linked to a 24% reduction in type 2 diabetes (T2D) incidence among women with prior gestational diabetes, compared with standard of care.

Investigators writing in BMJ Open called for “a complete restoration of FOURIER trial data.” Amgen, the maker of evolocumab, said it stood by the data.

This study investigated the effects of antimicrobial therapy among patients with non–small cell lung cancer (NSCLC) who received immunotherapy with a checkpoint inhibitor or chemotherapy plus immunotherapy (CIT).

The panel shares insights into the evolution of treatment strategies for patients with diabetes.

A panel of experts discuss considerations in insurance coverage for the treatment of patients with diabetes.

Brea C. Lipe, MD, highlights considerations for frail patients when treating for MM.

Medical experts explore the SWOG-S0777 trial and present an overview of daratumumab in combination with lenalidomide and dexamethasone (DRd) vs bortezomib, lenalidomide, and low-dose dexamethasone (VRd).

Inhaler technique informs health care outcomes in COPD management and should be a primary focus in patient education priorities.

Treatment pathways, including escalation and de-escalation of therapy, for patients with COPD are explored by a panel of medical experts.

Patient advocate Paige Nues elaborates on the patient journey associated with a Rett syndrome diagnosis.

Paige Nues, from the International Rett Syndrome Foundation, provides insights on the diagnostic journey for patients with Rett syndrome.

Drs Weaver and Chitre discuss aligning key considerations for payers and goals of therapy for patients in the treatment of MDD.

Drs Weaver and Chitre share strategies to support MDD treatment adherence across their patient populations.

M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, discusses the benefits of de-escalating treatment for patients with multiple myeloma.

Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

This year’s most-read articles on chronic obstructive pulmonary disease (COPD) includes researchon early interventions and possible health policy solutions.